Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Sinntaxis logo — Discovering, developing and commercialising novel therapeuti...

Sinntaxis

Discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.

Founded 2017 Sweden Sweden 4 employees Seed Total: $500.00K Biotechnology, Health Care +1

General Information

Company Name Sinntaxis
Founded Year 2017
Location Sweden Sweden
Employees 4
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Sinntaxis. To contact Sinntaxis, visit sinntaxis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Sinntaxis compare?

A PDF of Sinntaxis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Sinntaxis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Sinntaxis

Sinntaxis is a biotechnology startup based in Sweden, established in 2017 by scientists at Lund University and LU Holding AB. Specializing in the discovery, development, and commercialization of novel therapeutics to enhance the recovery of brain functions after stroke, the company is managed by a team with extensive experience in neuroscience/stroke research, pharmaceutical drug development, and business development.

The company has an established discovery platform for preclinical studies of stroke recovery and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery. Additionally, Sinntaxis has cultivated a global network of Key Opinion Leaders spanning from experimental research to clinical trials in the domain of stroke recovery.

Sinntaxis secured its Venture Round investment on 08 September 2020, with the backing of LU Innovation. With its focused approach on addressing unmet needs in the biotechnology and healthcare sectors, Sinntaxis is poised to make a significant impact in the realm of stroke recovery therapeutics.

Business keywords: therapeutics, stroke recovery, neuroscience, pharmaceutical, drug development, preclinical studies, metabotropic glutamate receptor 5, IP filing, Key Opinion Leaders, clinical trials, brain function recovery, experimental research, commercialisation, Lund University, LU Holding AB

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
LU Innovation
08 Sep 2020
Grant kr500.00K 2
SmiLe Venture Hub
SmiLe Venture Hub, Horizon 2020
26 Nov 2018

Sinntaxis Alternatives & Competitors

View All Alternatives
Sinntaxis vs
Oncorena AB
Oncorena AB Sweden

Developing a first-in-class treatment for advanced renal cancer

Venture round
10 employees
Biotechnology, Health Care
Sinntaxis vs
Raptor Pharmaceuticals
Raptor Pharmaceuticals

Embarking on a journey to better health through innovative biotechnology solutions for brain, geneti...

Post-IPO Equity
Biopharma, Biotechnology
Sinntaxis vs
ICONEUS
ICONEUS France

Delivering functional ultrasound (fUS) imaging solutions to help scientists understand the Brain fun...

Venture round
38 employees
Biotechnology, Health Care
View all alternatives

FAQ About Sinntaxis

Discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.
Sinntaxis was founded in 2017.
Sinntaxis is headquartered in Sweden.
Sinntaxis operates in Biotechnology, Health Care and Health and Wellness. Its work centres on therapeutics, stroke recovery, neuroscience and pharmaceutical.
Sinntaxis has approximately 4 employees.
Sinntaxis has completed 2 funding rounds, raising a total of $500.00K. The latest funding stage is Seed.
Top alternatives and competitors to Sinntaxis include Oncorena AB, Raptor Pharmaceuticals, ICONEUS, Amyl Therapeutics, Balance Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sinntaxis and Oncorena AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Sinntaxis, https://bouncewatch.com/company/sinntaxis, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes